GlassScriptPhysician profile
Gerald James Ortiz
NPI 1003805128
$17,591.32
in general payments reported to CMS, 2019-2025
20 companies · $3,419 in 2025
The $3,419 reported for 2025 was more than what 78% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,579 · 2020: $761 · 2021: $2,968 · 2022: $1,678 · 2023: $754 · 2024: $2,432 · 2025: $3,419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $4,322 · Food and Beverage: $2,283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $4,322.37 |
| Food and Beverage | $2,282.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Prodigy Surgical Distribution, INC. | $8,700.93 | 2019-2025 | |
| Arthrex, INC. | $7,317.65 | 2019-2025 | |
| Stryker Corporation | $401.56 | 2019-2023 | T2, Axsos, Hoffmann |
| Amgen INC. | $207.63 | 2019-2024 | Krystexxa, Evenity, Prolia |
| Ferring Pharmaceuticals INC. | $192.80 | 2020-2025 | Euflexxa |
| Depuy Synthes Sales INC. | $140.05 | 2019-2024 | Monovisc, Orthovisc |
| Treace Medical Concepts, INC. | $108.75 | 2023-2025 | |
| Dynasplint Systems INC. | $100.29 | 2022 | |
| Acumed LLC | $78.48 | 2024 | Acumed, Osteomed |
| Kowa Pharmaceuticals America, INC. | $54.71 | 2022-2023 | Seglentis |
| Zimmer Biomet Holdings, INC. | $53.25 | 2022 | |
| Medacta USA, INC. | $51.92 | 2022 | |
| Fidia Pharma USA INC. | $44.55 | 2019-2023 | Hymovis, Triluron |
| Pacira Therapeutics, INC. | $31.60 | 2021 | |
| Djo, LLC | $25.97 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $18.08 | 2019 | |
| Smith+Nephew, INC. | $17.81 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $16.72 | 2024 | |
| Horizon Therapeutics Plc | $15.29 | 2021 | |
| Bioventus LLC | $13.28 | 2023 | Durolane |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Ortiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.